following a full submission considered under the orphan equivalent process:
fostamatinib (Tavlesse®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
SMC restriction: for the treatment of patients with severe symptomatic ITP or with a high risk of bleeding who have not had a suitable response to other therapies, including a thrombopoietin receptor‐agonist (TPO-RA), or where use of a TPO-RA is not appropriate.
Fostamatinib has been shown to be significantly more effective than placebo in raising and maintaining platelet counts at (or above) a minimum target level in previously-treated patients with ITP.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- fostamatinib (Tavlesse)
- SMC ID:
Treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments.
- Pharmaceutical company
- Grifols UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Date advice published
- 18 January 2021